Shanghai Matwings Technology Co., Ltd., a global leader in AI-driven protein design, announced the completion of Series A funding rounds, raising tens of millions of USD.
The round was led by Qiming Venture Partners.
Founded in 2021 by an elite team from Shanghai Jiao Tong University, Matwings is one of the earliest companies to focus on AI protein models. It is pioneering a new frontier in protein engineering with its proprietary AI-based general protein design platform, AccelProtein™, which directly predicts protein functionality beyond the structural data. By predicting functionality, AccelProtein™ offers a new approach for acquiring high-functioning proteins. To date, the company has engineered more than 30 proteins either proprietary or co-developed with its stakeholders, and more than 40 ongoing projects across various applications in pharmaceutical industries and synthetic biology industries, e.g. key enzymes and proteins for CMC, innovative Biologics, synthetic biology and more.
The company is actively seeking global partnerships to jointly develop and commercialize new products.
FinSMEs
02/01/2025